Toenail Onychomycosis: Treatment Options Evaluated
A total of 26 RCTs with 8136 patients were included in this network meta analysis.
Fungal Infections
CDC: Superbug Fungus Has Sickened 600 Americans
Candida auris can survive on surfaces after routine cleaning and is often drug-resistant
New Drug Product: Tolsura
This slideshow reviews drug information for Tolsura. This slideshow reviews drug information for Tolsura.
Treatment for Cryptococcosis Gets FDA’s Orphan Drug Designation
The Food and Drug Administration (FDA) has granted Orphan Drug designation to APX001 (Amplyx Pharmaceuticals) for the treatment of cryptococcosis.
New Treatment Option for Serious Fungal Infections Now Available
Tolsura, which contains the azole antifungal itraconazole, is formulated using the Company’s proprietary SUBA (SUper-BioAvailable) technology which improves the bioavailability of poorly soluble drugs.
FDA Approves Tolsura for the Treatment of Certain Systemic Fungal Infections
Tolsura is a new formulation of itraconazole, an azole antifungal, that utilizes the Company’s proprietary SUBA (SUper-BioAvailable) technology to improve the bioavailability of poorly soluble drugs.
Hypoglycemia Following Antifungal Tx in Patient With Type 1 Diabetes
“This is the first report of decreased insulin requirements in a patient with T1DM correlating with micafungin administration,” noted the authors.
Rezafungin Gets Fast Track, QIDP Status for Prevention of Invasive Fungal Infections
The Phase 3 ReSPECT prophylaxis trial of rezafungin in patients undergoing allogeneic bone marrow transplantation is anticipated to start in the first quarter of 2019.
NICU Antibiotic Use Rates Declined From 2013 to 2016
There was no correlation between the 2016 AUR and either proven infection or necrotizing enterocolitis. However, there was an association between the 2016 regional NICU AUR and surgical volume, mortality rate, and average length of stay
CDC: Greater Awareness of Valley Fever Needed Nationally
Seven in 10 patients had another condition diagnosed before coccidioidomycosis testing occurred, of whom the vast majority (83%) were prescribed antibacterial medications, 43% were hospitalized, and 29% had culture-positive coccidioidomycosis.
